Sodium Pyruvate

丙酮酸钠

Report date: 2025/11/17 15:14:34
NME

Base Information

Drug NameSodium Pyruvate
Drug Alias NameEmphyClear COPD/Asthma Spray丙铜酸钠EmphyClear COPD Oral SpraySodium pyruvate inhalationEmphyclear steroidal nasal spray +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReactive oxygen species inhibitors
TargetsReactive oxygen species
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeIdiopathic Pulmonary Fibrosis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEmphycorp Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCellular SciencesJiangsu Changtai Pharmaceutical Co Ltd
Inactive CompaniesUniversity Of California San FranciscoNational Institutes Of HealthUniversity Of Minnesota +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeIdiopathic Pulmonary Fibrosis +[4] 
Inactive IndicationsAsthmaCystic FibrosisProstatic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia